Finoriq research workspace
AIM ImmunoTech Inc. (AIM) Historical Metrics
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics. Review AIM valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
- Company
- AIM ImmunoTech Inc. (AIM)
- Ticker
- AIM
- Market Cap
- $6.9M
- Latest Price
- $0.2487
- Industry
- Biotech & Pharma
AIM ImmunoTech Inc. (AIM) Current Valuation Metrics
Static valuation preview for AIM ImmunoTech Inc. (AIM). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 85.1x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -166.0% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -141.5% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 3.76x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.